Eli Lilly and Co. revealed in a regulatory filing that the HHS Office of Inspector General asked for a "wide range of documents and information" related to government reimbursement for its cancer drug Alimta. Lilly is also facing a congressional inquiry into its role in the exclusion of an expert on the FDA panel assigned to review its blood thinner Effient for approval.

Related Summaries